Each patient received a smartphone with an insulin dose advisor (IDA) and with (G3 group) or without (G2 group) the telemonitoring/teleconsultation function. Patients were classified as 鈥渉igh users鈥?if the proportion of 鈥渋nformed鈥?meals using the IDA exceeded 67% (median) and as 鈥渓ow users鈥?if not. Also analyzed was the respective impact of the IDA function and teleconsultations on the final HbA1c levels.
Among the high users, the proportion of informed meals remained stable from baseline to the end of the study 6 months later (from 78.1 卤 21.5% to 73.8 卤 25.1%; P = 0.107), but decreased in the low users (from 36.6 卤 29.4% to 26.7 卤 28.4%; P = 0.005). As expected, HbA1c improved in high users from 8.7% [range: 8.3-9.2%] to 8.2% [range: 7.8-8.7%] in patients with (n = 26) vs without (n = 30) the benefit of telemonitoring/teleconsultation (鈭?.49 卤 0.60% vs 鈭?.52 卤 0.73%, respectively; P = 0.879). However, although HbA1c also improved in low users from 9.0% [8.5-10.1] to 8.5% [7.9-9.6], those receiving support via teleconsultation tended to show greater improvement than the others (鈭?.93 卤 0.97 vs 鈭?.46 卤 1.05, respectively; P = 0.084).
The Diabeo system improved glycaemic control in both high and low users who avidly used the IDA function, while the greatest improvement was seen in the low users who had the motivational support of teleconsultations.